Related Experiment Video
Updated: Jul 7, 2026

A Co-culture Method to Investigate the Crosstalk Between X-ray Irradiated Caco-2 Cells and PBMC
Published on: January 30, 2018
CBX2 as a therapeutic target in colorectal cancer: insights into the altered chromatin accessibility via
Bangting Wang1,2, Shijie Zhang1, Yumeng Guo3
1Digestive Endoscopy Department, The First Affiliated Hospital with Nanjing Medical University and Jiangsu Province Hospital, Nanjing, Jiangsu, China.
Abstract:
Chromobox homolog 2 (CBX2), a component of the polycomb repressive complex 1, is overexpressed in various cancers, but its specific role in colorectal cancer (CRC) is not fully understood. This study aimed to characterize the functional and regulatory roles of CBX2 in CRC. Tissue microarray analysis revealed the elevated CBX2 levels in tumor compared to adjacent normal tissues, which is significantly correlated with poor prognosis. Gain and loss of function studies demonstrated that CBX2 significantly promoted CRC progression and chemoresistance in cell lines, patient-derived CRC organoids and xenografts. In the AOM/DSS mouse model, treatment with the innovatively-developed cy5-PBAE/siCBX2 nanoparticle significantly reduced tumor aggressiveness. Mechanistic studies unveiled that the transcription factor RUNX1 is the positive regulator of CBX2. RNA-seq, ATAC-seq and CUT & RUN results indicated CBX2 knockdown induced epigenetic changes, especially alterations in chromatin accessibility. Moreover, we further identified MAP4K1 as a target gene of RUNX1-CBX2, with significant clinical and prognostic relevance in CRC. Collectively, these findings suggest the pivotal role of RUNX1-CBX2-MAP4K1 axis in CRC progression and underscore CBX2 as a promising biomarker and therapeutic target. The regulatory function of CBX2 on chromatin accessibility and the role of the RUNX1-CBX2-MAP4K1-pERK axis in the progression of colorectal cancer.
Insights
Chromobox homolog 2 (CBX2) promotes colorectal cancer (CRC) progression and chemoresistance. Targeting the RUNX1-CBX2-MAP4K1 axis offers a promising therapeutic strategy for CRC.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- Chromobox homolog 2 (CBX2) is implicated in various cancers.
- Its specific role in colorectal cancer (CRC) requires further elucidation.
Purpose of the Study:
- To investigate the functional and regulatory roles of CBX2 in colorectal cancer (CRC).
- To identify key molecular pathways involving CBX2 in CRC progression.
Main Methods:
- Tissue microarray analysis, in vitro and in vivo functional studies (cell lines, organoids, xenografts, mouse models).
- RNA-sequencing (RNA-seq), Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq), CUT & RUN assays.
- Identification of regulatory networks and target genes.
Main Results:
- CBX2 is overexpressed in CRC tumors and correlates with poor prognosis.
- CBX2 promotes CRC progression and chemoresistance.
- RUNX1 is a positive regulator of CBX2, and the RUNX1-CBX2-MAP4K1 axis is crucial for CRC.
- CBX2 influences epigenetic modifications and chromatin accessibility.
Conclusions:
- CBX2 plays a pivotal role in colorectal cancer (CRC) progression.
- The RUNX1-CBX2-MAP4K1 axis is a key pathway in CRC.
- CBX2 is a potential biomarker and therapeutic target for CRC.
Related Concept Videos
Epigenetic Regulation
X-Inactivation
Inheritance of Chromatin Structures
Abnormal Proliferation
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Epigenetic Regulation
X-chromosome...

